A Phase 2 interventional study of Placebo Comparator and CM512 in Atopic Dermatitis, sponsored by Keymed Biosciences Co.Ltd. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-08-17.
Sponsored by Keymed Biosciences Co.Ltd · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Dermatitis, Atopic by Keymed Biosciences Co.Ltd — 4 open to participants now, 5 under way, 3 of them phase 3. Dermatitis, Atopic · Keymed Biosciences Co.Ltd.
Among the 18 studies in Dermatitis, Atopic by Keymed Biosciences Co.Ltd, this one is the 7th largest by planned enrollment, is one of 4 that started in 2025, is one of 9 in phase 2, and was the 15th registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →4 of the 18 studies in Dermatitis, Atopic by Keymed Biosciences Co.Ltd are open now, in 1 country. Recruiting first, the newest first:
Keymed Biosciences Co.Ltd · Sites in China
Ages 18+
Keymed Biosciences Co.Ltd · Sites in China
Ages 2–12
Keymed Biosciences Co.Ltd · Sites in China
Ages 2–11
By country, each count listing its studies:
Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 12 · Phase 3 5
First in 2020; this study’s year is marked. 4 started in 2025.
This study's planned enrollment of 200 is above the median of 82 across 1,248 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 170 across the 18 interventional studies. Of the 10 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Keymed Biosciences Co.Ltd is the lead sponsor of 68 studies on the registry; 34 are open to participants now.
1 of the studies in Dermatitis, Atopic by Keymed Biosciences Co.Ltd that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07106372Phase 3Keymed Biosciences Co.LtdA Study of Stapokibatrt in Children Subjects With Atopic Dermatitis | 2027-02 |
Add it to your calendar (.ics) → With an account.
Among the 18 studies in Dermatitis, Atopic by Keymed Biosciences Co.Ltd, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A Phase 2 study designed to evaluate the efficacy and safety of CM512 in adult patients with moderate-to-severe Atopic Dermatitis (AD).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Investigator's Global Assessment (IGA) score of≥3 at Screening and Baseline visits;
Exclusion Criteria:
Drug: Placebo Comparator
Biological: CM512
Biological: CM512
Biological: CM512
Drug: Placebo Comparator
Placebo subcutaneous injection
CM512 subcutaneous injection
Percent change from Baseline in Eczema Area and Severity Index (EASI) at Week 24
The EASI score is used to measure the severity and extent of AD and measured erythema, edema/papulation, excoriation and lichenification on 4 anatomic regions of the body: head and neck, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD.
Time frame: Baseline, Week 24
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2025 (actual). Primary completion is estimated for Jul 2026, 12 months after the start.
Of 196 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's planned 12 months is close to that.
Counting every sponsor, half of 224 studies reached it within 14 months; a quarter within 10 and three quarters within 19.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: CM512